Pulse Biosciences, Inc.’s PLSE share price has dipped by 11.28%, which has investors questioning if this is right time to buy.

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the late ...

Pulse Biosciences, Inc. (Nasdaq: PLSE) , a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans to present at the ...

Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA ...

(RTTNews) - Pulse Biosciences, Inc. (PLSE), a novel bioelectric medicine company, Tuesday announced the appointment of Jon Skinner as Chief Financial Officer, with effect from February 3.

Pulse Biosciences (PLSE) announced the appointment of Jon Skinner as Chief Financial Officer, effective February 3. “I am excited to announce Jon as our next CFO, further building upon our ...

M IAMI - Pulse Biosciences, Inc. (NASDAQ:PLSE), a biotech company with a market capitalization of $1.08 billion and an impressive 112% stock return over the past year, has announced promising ...

Mr. Skinner brings a wealth of experience to Pulse Biosciences, having most recently served as Vice President, FP&A and Investor Relations at Copeland, a private equity-backed industrial company.

Pulse Biosciences has hired Jon Skinner as the bioelectric medicine company's new chief financial officer. Pulse on Tuesday said Skinner most recently served as vice president of financial ...